Aclaris Therapeutics (ACRS) Return on Sales (2017 - 2025)
Historic Return on Sales for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 4.65%.
- Aclaris Therapeutics' Return on Sales fell 27000.0% to 4.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.22%, marking a year-over-year decrease of 78100.0%. This contributed to the annual value of 7.05% for FY2024, which is 42200.0% down from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Return on Sales is 4.65%, which was down 27000.0% from 9.22% recorded in Q2 2025.
- Aclaris Therapeutics' Return on Sales' 5-year high stood at 0.11% during Q4 2023, with a 5-year trough of 17.02% in Q2 2023.
- Over the past 5 years, Aclaris Therapeutics' median Return on Sales value was 9.87% (recorded in 2021), while the average stood at 8.71%.
- In the last 5 years, Aclaris Therapeutics' Return on Sales tumbled by -158700bps in 2021 and then skyrocketed by 130500bps in 2024.
- Aclaris Therapeutics' Return on Sales (Quarter) stood at 15.25% in 2021, then surged by 75bps to 3.75% in 2022, then soared by 97bps to 0.11% in 2023, then crashed by -9917bps to 10.59% in 2024, then skyrocketed by 56bps to 4.65% in 2025.
- Its Return on Sales stands at 4.65% for Q3 2025, versus 9.22% for Q2 2025 and 10.94% for Q1 2025.